Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly undervalued vs peers
About
Samyang Holdings Corporation, a diversified conglomerate founded in Seoul, South Korea, in 1924, engages in a wide array of activities through its various subsidiaries. The company's operations span the chemical, food, packaging, pharmaceutical, and IT service sectors. Its chemical division manufactures an extensive range of advanced materials, including value-added chemicals, terephthalic acid, various polycarbonate (PC) resins, bisphenol-A, and specialized engineering plastics. They also produce PC and polybutylene terephthalate compounds, PET bottles, and long fiber reinforced thermoplastics. In the food business, Samyang offers both health and wellness products and starch-based sugars. The company also extends into consumer services, operating the Seven Springs salad and brunch restaurant concept, along with Café Seven Springs bakeries. Its pharmaceutical arm develops and markets anti-cancer treatments such as Genexol and Nanoxel PM, in addition to medical devices like the NicoStop smoking cessation patch and biodegradable surgical sutures, including Trisorb and Monosorb. Samyang's products have a global reach, being exported to over 80 countries. Furthermore, Samyang provides comprehensive IT services, offering consulting for system management and integration, e-business solutions, and enterprise software (ERP, e-HR, MES, and mobile services) to clients in the public, finance, and manufacturing industries.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA, und